| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Myocardial Perfusion Imaging | 13 | 2023 | 53 | 2.330 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 12 | 2024 | 200 | 1.730 |
Why?
|
| Echocardiography | 7 | 2023 | 511 | 1.680 |
Why?
|
| Heart Valve Diseases | 5 | 2021 | 95 | 1.620 |
Why?
|
| Echocardiography, Three-Dimensional | 2 | 2024 | 46 | 1.570 |
Why?
|
| Coronary Artery Disease | 6 | 2015 | 326 | 1.330 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2024 | 99 | 1.250 |
Why?
|
| Aortic Valve Insufficiency | 2 | 2021 | 43 | 0.970 |
Why?
|
| Hypertension, Pulmonary | 2 | 2021 | 97 | 0.940 |
Why?
|
| Heart | 4 | 2023 | 295 | 0.910 |
Why?
|
| Aortic Valve Stenosis | 4 | 2021 | 195 | 0.730 |
Why?
|
| Image Enhancement | 2 | 2014 | 194 | 0.730 |
Why?
|
| Echocardiography, Doppler | 3 | 2019 | 133 | 0.700 |
Why?
|
| Aorta | 1 | 2021 | 114 | 0.670 |
Why?
|
| Exercise Test | 5 | 2016 | 257 | 0.670 |
Why?
|
| Aortic Valve | 3 | 2021 | 192 | 0.600 |
Why?
|
| Radiopharmaceuticals | 3 | 2024 | 192 | 0.530 |
Why?
|
| 3-Iodobenzylguanidine | 2 | 2014 | 3 | 0.530 |
Why?
|
| Hyperaldosteronism | 1 | 2016 | 9 | 0.490 |
Why?
|
| Mesalamine | 1 | 2015 | 4 | 0.470 |
Why?
|
| Humans | 43 | 2024 | 65502 | 0.460 |
Why?
|
| Fluorodeoxyglucose F18 | 3 | 2024 | 102 | 0.460 |
Why?
|
| Positron Emission Tomography Computed Tomography | 3 | 2024 | 61 | 0.450 |
Why?
|
| Vascular Endothelial Growth Factor C | 1 | 2015 | 21 | 0.450 |
Why?
|
| Sympathetic Nervous System | 2 | 2014 | 35 | 0.450 |
Why?
|
| Chest Pain | 1 | 2015 | 85 | 0.440 |
Why?
|
| Consensus | 3 | 2024 | 184 | 0.430 |
Why?
|
| Neuropilin-2 | 1 | 2015 | 40 | 0.430 |
Why?
|
| Myocarditis | 1 | 2015 | 71 | 0.430 |
Why?
|
| Radiation Protection | 1 | 2014 | 26 | 0.420 |
Why?
|
| Exercise | 2 | 2012 | 964 | 0.420 |
Why?
|
| Artifacts | 1 | 2015 | 127 | 0.420 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 3 | 2024 | 11 | 0.410 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2015 | 182 | 0.410 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2015 | 205 | 0.410 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2015 | 112 | 0.410 |
Why?
|
| Ventricular Outflow Obstruction | 1 | 2015 | 120 | 0.400 |
Why?
|
| Purines | 1 | 2012 | 43 | 0.380 |
Why?
|
| Pyrazoles | 1 | 2012 | 90 | 0.360 |
Why?
|
| Heart Failure | 2 | 2023 | 942 | 0.350 |
Why?
|
| Positron-Emission Tomography | 1 | 2012 | 228 | 0.340 |
Why?
|
| Mitral Valve | 3 | 2024 | 130 | 0.340 |
Why?
|
| Heart Ventricles | 3 | 2023 | 267 | 0.330 |
Why?
|
| Stroke Volume | 3 | 2019 | 338 | 0.330 |
Why?
|
| Athletes | 1 | 2012 | 109 | 0.320 |
Why?
|
| Exercise Therapy | 1 | 2011 | 104 | 0.320 |
Why?
|
| Cardiovascular Infections | 3 | 2024 | 3 | 0.320 |
Why?
|
| Predictive Value of Tests | 5 | 2024 | 1113 | 0.310 |
Why?
|
| Endocarditis | 3 | 2024 | 29 | 0.300 |
Why?
|
| Neurons | 1 | 2014 | 949 | 0.280 |
Why?
|
| Myocardial Infarction | 1 | 2014 | 924 | 0.260 |
Why?
|
| Ventricular Function, Left | 2 | 2019 | 275 | 0.250 |
Why?
|
| Leukocytes | 2 | 2024 | 104 | 0.250 |
Why?
|
| Hospitalization | 1 | 2014 | 1391 | 0.250 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2015 | 2250 | 0.240 |
Why?
|
| Reproducibility of Results | 6 | 2024 | 1698 | 0.240 |
Why?
|
| Prognosis | 5 | 2024 | 1795 | 0.230 |
Why?
|
| Male | 19 | 2021 | 31057 | 0.230 |
Why?
|
| Ventricular Remodeling | 3 | 2023 | 90 | 0.230 |
Why?
|
| Vasodilator Agents | 2 | 2016 | 71 | 0.210 |
Why?
|
| Angina, Stable | 2 | 2014 | 11 | 0.210 |
Why?
|
| Female | 18 | 2021 | 34105 | 0.210 |
Why?
|
| Delphi Technique | 1 | 2024 | 110 | 0.200 |
Why?
|
| Pericardium | 1 | 2023 | 35 | 0.200 |
Why?
|
| Hypertension | 2 | 2021 | 613 | 0.200 |
Why?
|
| Risk Assessment | 4 | 2015 | 2102 | 0.200 |
Why?
|
| Heart Atria | 1 | 2023 | 138 | 0.190 |
Why?
|
| Middle Aged | 12 | 2021 | 18271 | 0.190 |
Why?
|
| Registries | 2 | 2017 | 904 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2014 | 425 | 0.170 |
Why?
|
| Dilatation | 1 | 2021 | 34 | 0.170 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2021 | 124 | 0.160 |
Why?
|
| Pulmonary Artery | 1 | 2021 | 99 | 0.160 |
Why?
|
| Bioprosthesis | 1 | 2021 | 41 | 0.160 |
Why?
|
| Heart Valve Prosthesis | 1 | 2021 | 118 | 0.150 |
Why?
|
| Technetium Tc 99m Sestamibi | 1 | 2019 | 34 | 0.150 |
Why?
|
| Atrial Pressure | 1 | 2019 | 6 | 0.150 |
Why?
|
| Ventricular Pressure | 1 | 2019 | 31 | 0.150 |
Why?
|
| Heart Valves | 1 | 2018 | 26 | 0.140 |
Why?
|
| Risk Factors | 6 | 2021 | 5440 | 0.140 |
Why?
|
| Transcatheter Aortic Valve Replacement | 1 | 2021 | 116 | 0.140 |
Why?
|
| Cardiac Catheterization | 2 | 2019 | 305 | 0.140 |
Why?
|
| Retrospective Studies | 6 | 2021 | 6877 | 0.140 |
Why?
|
| Aged, 80 and over | 6 | 2021 | 5619 | 0.140 |
Why?
|
| Hemodynamics | 2 | 2016 | 257 | 0.140 |
Why?
|
| Acetanilides | 2 | 2014 | 3 | 0.130 |
Why?
|
| Protein Multimerization | 2 | 2015 | 182 | 0.130 |
Why?
|
| Data Accuracy | 1 | 2017 | 31 | 0.130 |
Why?
|
| Adult | 7 | 2021 | 17399 | 0.130 |
Why?
|
| Piperazines | 2 | 2014 | 86 | 0.130 |
Why?
|
| Inservice Training | 1 | 2017 | 86 | 0.120 |
Why?
|
| Aldosterone | 1 | 2016 | 18 | 0.120 |
Why?
|
| Mathematics | 1 | 2016 | 34 | 0.120 |
Why?
|
| Coronary Circulation | 1 | 2016 | 55 | 0.120 |
Why?
|
| Sensitivity and Specificity | 3 | 2015 | 1171 | 0.120 |
Why?
|
| Follow-Up Studies | 3 | 2019 | 2509 | 0.120 |
Why?
|
| Viridans Streptococci | 1 | 2015 | 5 | 0.120 |
Why?
|
| Medical Laboratory Personnel | 1 | 2015 | 10 | 0.120 |
Why?
|
| Vascular Fistula | 1 | 2015 | 8 | 0.120 |
Why?
|
| Acute Coronary Syndrome | 1 | 2019 | 254 | 0.120 |
Why?
|
| Shock | 1 | 2015 | 33 | 0.120 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 997 | 0.110 |
Why?
|
| Endocarditis, Bacterial | 1 | 2015 | 37 | 0.110 |
Why?
|
| Streptococcal Infections | 1 | 2015 | 80 | 0.110 |
Why?
|
| Lafora Disease | 1 | 2014 | 1 | 0.110 |
Why?
|
| Heart Defects, Congenital | 1 | 2016 | 106 | 0.110 |
Why?
|
| Aortic Diseases | 1 | 2015 | 65 | 0.110 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 1 | 2014 | 7 | 0.110 |
Why?
|
| Calcinosis | 1 | 2015 | 86 | 0.110 |
Why?
|
| Glycogen | 1 | 2014 | 42 | 0.110 |
Why?
|
| Treatment Outcome | 5 | 2021 | 5818 | 0.110 |
Why?
|
| Nausea | 1 | 2015 | 112 | 0.110 |
Why?
|
| Dyspnea | 1 | 2015 | 124 | 0.110 |
Why?
|
| Vomiting | 1 | 2015 | 139 | 0.110 |
Why?
|
| Protein Isoforms | 1 | 2015 | 204 | 0.110 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2015 | 67 | 0.110 |
Why?
|
| Triage | 1 | 2015 | 127 | 0.110 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 128 | 0.110 |
Why?
|
| ROC Curve | 3 | 2023 | 295 | 0.100 |
Why?
|
| Standard of Care | 1 | 2014 | 28 | 0.100 |
Why?
|
| Aged | 9 | 2019 | 14955 | 0.100 |
Why?
|
| Proteolysis | 1 | 2015 | 159 | 0.100 |
Why?
|
| Health Status Indicators | 1 | 2014 | 94 | 0.100 |
Why?
|
| Drug Costs | 1 | 2014 | 57 | 0.100 |
Why?
|
| Protein Binding | 2 | 2015 | 1651 | 0.100 |
Why?
|
| Electric Countershock | 1 | 2014 | 105 | 0.100 |
Why?
|
| Multimodal Imaging | 2 | 2024 | 73 | 0.100 |
Why?
|
| Radiation Dosage | 1 | 2014 | 140 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2015 | 226 | 0.100 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 193 | 0.100 |
Why?
|
| Adenosine A2 Receptor Agonists | 1 | 2012 | 7 | 0.100 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 194 | 0.090 |
Why?
|
| Proportional Hazards Models | 2 | 2013 | 741 | 0.090 |
Why?
|
| Binding Sites | 1 | 2015 | 930 | 0.090 |
Why?
|
| Quality Improvement | 1 | 2017 | 468 | 0.090 |
Why?
|
| Coronary Disease | 1 | 2013 | 248 | 0.090 |
Why?
|
| Physical Endurance | 1 | 2012 | 48 | 0.090 |
Why?
|
| Exercise Tolerance | 1 | 2012 | 84 | 0.090 |
Why?
|
| Coronary Angiography | 1 | 2012 | 211 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2015 | 1618 | 0.090 |
Why?
|
| Cardiomyopathies | 1 | 2013 | 132 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2015 | 2016 | 0.090 |
Why?
|
| Sex Factors | 2 | 2012 | 997 | 0.090 |
Why?
|
| Myocardium | 1 | 2013 | 298 | 0.090 |
Why?
|
| Defibrillators, Implantable | 1 | 2014 | 273 | 0.080 |
Why?
|
| Morbidity | 1 | 2011 | 111 | 0.080 |
Why?
|
| Databases, Factual | 1 | 2014 | 878 | 0.080 |
Why?
|
| Length of Stay | 1 | 2014 | 830 | 0.080 |
Why?
|
| Confidence Intervals | 1 | 2010 | 239 | 0.080 |
Why?
|
| United States | 4 | 2024 | 8126 | 0.070 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 555 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2012 | 366 | 0.070 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 739 | 0.070 |
Why?
|
| Cardiomyopathy, Hypertrophic | 1 | 2016 | 789 | 0.070 |
Why?
|
| Cardiovascular Diseases | 1 | 2014 | 866 | 0.060 |
Why?
|
| Disease Progression | 1 | 2011 | 1216 | 0.060 |
Why?
|
| Quality of Life | 1 | 2014 | 1271 | 0.060 |
Why?
|
| Age Factors | 1 | 2010 | 1591 | 0.060 |
Why?
|
| Echocardiography, Transesophageal | 2 | 2015 | 121 | 0.050 |
Why?
|
| Prevalence | 2 | 2021 | 1440 | 0.050 |
Why?
|
| Ranolazine | 2 | 2014 | 2 | 0.050 |
Why?
|
| Prosthesis-Related Infections | 1 | 2024 | 34 | 0.050 |
Why?
|
| Cardiac Resynchronization Therapy | 1 | 2023 | 20 | 0.050 |
Why?
|
| Time Factors | 3 | 2015 | 3785 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1672 | 0.050 |
Why?
|
| Double-Blind Method | 2 | 2014 | 748 | 0.050 |
Why?
|
| Enzyme Inhibitors | 2 | 2014 | 376 | 0.050 |
Why?
|
| Phantoms, Imaging | 1 | 2023 | 232 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2013 | 612 | 0.040 |
Why?
|
| Societies, Medical | 1 | 2024 | 403 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2014 | 757 | 0.040 |
Why?
|
| Prosthesis Design | 1 | 2021 | 228 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2023 | 694 | 0.040 |
Why?
|
| Diastole | 1 | 2019 | 91 | 0.040 |
Why?
|
| Algorithms | 1 | 2024 | 1049 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2014 | 2626 | 0.030 |
Why?
|
| Connecticut | 1 | 2015 | 89 | 0.030 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2015 | 19 | 0.030 |
Why?
|
| Debridement | 1 | 2015 | 33 | 0.030 |
Why?
|
| Echocardiography, Doppler, Color | 1 | 2015 | 28 | 0.030 |
Why?
|
| New York | 1 | 2015 | 144 | 0.030 |
Why?
|
| Cardiopulmonary Bypass | 1 | 2015 | 59 | 0.030 |
Why?
|
| Observer Variation | 1 | 2015 | 215 | 0.030 |
Why?
|
| Substance Abuse, Intravenous | 1 | 2015 | 84 | 0.030 |
Why?
|
| Oligosaccharides | 1 | 2014 | 55 | 0.030 |
Why?
|
| Phosphates | 1 | 2014 | 100 | 0.030 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2015 | 186 | 0.030 |
Why?
|
| Placebos | 1 | 2014 | 72 | 0.030 |
Why?
|
| Cause of Death | 1 | 2015 | 223 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 261 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2014 | 207 | 0.030 |
Why?
|
| Global Health | 1 | 2015 | 183 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2014 | 63 | 0.030 |
Why?
|
| Crystallography, X-Ray | 1 | 2014 | 442 | 0.030 |
Why?
|
| Machine Learning | 1 | 2015 | 195 | 0.030 |
Why?
|
| Electrocardiography | 1 | 2016 | 558 | 0.020 |
Why?
|
| Perfusion | 1 | 2013 | 74 | 0.020 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2015 | 187 | 0.020 |
Why?
|
| Patient Selection | 1 | 2015 | 489 | 0.020 |
Why?
|
| Technetium | 1 | 2012 | 68 | 0.020 |
Why?
|
| Survival Rate | 1 | 2015 | 860 | 0.020 |
Why?
|
| False Positive Reactions | 1 | 2012 | 79 | 0.020 |
Why?
|
| Risk | 1 | 2013 | 380 | 0.020 |
Why?
|
| Echocardiography, Stress | 1 | 2012 | 15 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 1 | 2014 | 320 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2012 | 132 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2013 | 500 | 0.020 |
Why?
|
| Phosphorylation | 1 | 2014 | 977 | 0.020 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2013 | 163 | 0.020 |
Why?
|
| Ventricular Dysfunction, Left | 1 | 2013 | 168 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 880 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2013 | 212 | 0.020 |
Why?
|
| Anticoagulants | 1 | 2015 | 520 | 0.020 |
Why?
|
| Models, Molecular | 1 | 2014 | 1174 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2015 | 728 | 0.020 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 465 | 0.020 |
Why?
|
| Research Design | 1 | 2012 | 584 | 0.020 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 820 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 4815 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2014 | 2778 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2013 | 3344 | 0.010 |
Why?
|